Avicanna Inc (AVCN : TSX)
Common Stock
$0.14
CAD
-0.01 (-3.57%)
Last updated: 2026-06-16
AVCN
Avicanna Inc
WealthAwesomePerformance
1 Day
-3.57%
1 Week
+22.73%
1 Month
-3.57%
YTD
-38.64%
Key Statistics
Market Cap
$17.61M
52W High
$0.31
52W Low
$0.10
P/E Ratio
-
50 Day MA
$0.14
200 Day MA
$0.20
Beta
0.35
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/16/2026 | $0.14 | $0.14 | $0.13 | $0.14 | $0.14 | 264,028 |
| 6/15/2026 | $0.12 | $0.14 | $0.12 | $0.14 | $0.14 | 467,338 |
| 6/12/2026 | $0.11 | $0.13 | $0.11 | $0.13 | $0.13 | 527,788 |
| 6/11/2026 | $0.11 | $0.12 | $0.11 | $0.11 | $0.11 | 139,000 |
| 6/10/2026 | $0.11 | $0.12 | $0.11 | $0.11 | $0.11 | 29,000 |
| 6/9/2026 | $0.11 | $0.12 | $0.10 | $0.11 | $0.11 | 366,450 |
| 6/8/2026 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | 41,500 |
| 6/5/2026 | $0.12 | $0.12 | $0.11 | $0.12 | $0.12 | 185,500 |
| 6/4/2026 | $0.13 | $0.13 | $0.12 | $0.13 | $0.13 | 208,000 |
| 6/3/2026 | $0.13 | $0.13 | $0.12 | $0.13 | $0.13 | 154,564 |
Analyst Price Targets
Based on analyst covering AVCN
Wall Street analysts forecast AVCN stock price to rise 418.5% over the next 12 months.
Consensus
No RatingAvg. Target
C$0.70
+418.5% Upside
Current Price
C$0.14
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AVCN's historical volatility
30-Day Vol
77.9%
Annualized
90-Day Vol
63.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.11
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.13 | C$0.10 – C$0.17 |
| 60 trading days | C$0.12 | C$0.08 – C$0.18 |
| 90 trading days | C$0.11 | C$0.07 – C$0.18 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific cannabinoid-based candidates to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, as well as Trunerox, an indication-specific drug treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, it operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, as well as provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens; and collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
Financials
- Revenue (TTM)
- $25.83M
- EBITDA
- $-2.67M
- Profit Margin
- -12.09%
- ROE (TTM)
- -26.45%
- EPS (Diluted)
- -0.02
- Book Value
- 0.03
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About AVCN
Articles Featuring AVCN.TO
Latest articles and analysis covering AVCN.TO
Why Avicanna Inc stock is rising today
Avicanna Inc's stock has risen by 3.70% following a strategic investment from Splash Beverage Group, highlighting its potential in the cannabinoid biopharmaceutical market.
Why Avicanna Inc stock is sliding today
Avicanna Inc's stock fell 3.57% today, closing at CA$0.14, amid investor concerns about the company's financial health despite recent strategic investments.
Why Avicanna Inc stock is skyrocketing today
Avicanna Inc (AVCN.TO) saw its stock price soar by 12% in the last trading session, driven by a strategic investment from Splash Beverage Group and positive market sentiment surrounding the cannabinoid healthcare sector.
Why Avicanna Inc stock is skyrocketing today
Avicanna Inc. (AVCN.TO) has seen a remarkable 16% increase in its stock price, driven by strategic investments and advancements in cannabinoid healthcare. As the company continues to innovate, investors are optimistic about its future.
Why Avicanna Inc stock is rising today
Avicanna Inc's stock has risen by 4.55% in the last trading session, reflecting positive investor sentiment and potential growth in the cannabis market.
Why Avicanna Inc stock is rising today
Avicanna Inc's stock has risen by 4.35% today, closing at CA$0.12, reflecting increased investor confidence amid a challenging market landscape.
